Home > Insider Trading > Filing (0001999371-25-001562)

Filing Details

Accession Number:: 0001999371-25-001562
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2025-02-12 17:21:33
Reporting Period:: 2025-02-10

Filing Date:: 2025-02-12
Accepted Time:: 2025-02-12 17:21:33
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
2036042	Sionna Therapeutics Inc.	SION	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1099776	G James Coulter	C/O Tpg Inc. 301 Commerce Street, Suite 3300 Fort Worth TX 76102	No	No	Yes	No
1366946	Jon Winkelried	C/O Tpg Inc. 301 Commerce Street, Suite 3300 Fort Worth TX 76102	No	No	Yes	No
1903793	Tpg Gp A, Llc	C/O Tpg Inc. 301 Commerce Street, Suite 3300 Fort Worth TX 76102	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2025-02-10	4,875,547	$0.00	5,559,962	No	4	C	Indirect	See Explanation of Responses
Common Stock	Acquisiton	2025-02-10	1,125,000	$18.00	6,684,962	No	4	P	Indirect	See Explanation of Responses

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Explanation of Responses
No	4	P	Indirect	See Explanation of Responses

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series Seed Preferred Stock	Disposition	2025-02-10	1,276,276	$0.00	873,503	$0.00
Common Stock	Series A Preferred Stock	Disposition	2025-02-10	1,806,318	$0.00	1,236,272	$0.00
Common Stock	Series B Preferred Stock	Disposition	2025-02-10	2,275,528	$0.00	1,557,408	$0.00
Common Stock	Series C Preferred Stock	Disposition	2025-02-10	1,765,541	$0.00	1,208,364	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

Each of James G. Coulter and Jon Winkelried own entities that control TPG GP A, LLC (together with Messrs. Coulter and Winkelried, the "Reporting Persons"), which is the managing member of each of (i) TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., and (ii) Alabama Investments (Parallel) GP, LLC, which is the general partner of each of (a) Alabama Investments (Parallel), LP, (b) Alabama Investments (Parallel) Founder A, LP and (c) Alabama Investments (Parallel) Founder G, LP, which, collectively with TPG Group Holdings (SBS), L.P., Alabama Investments (Parallel), LP and Alabama Investments (Parallel) Founder A, LP, holds 100% of the shares of Class B common stock (which represents a majority of the combined voting power of the common stock) of TPG Inc.
TPG Inc. is the sole member of TPG GPCo, LLC, which is the sole member of TPG Holdings II-A, LLC, which is the general partner of TPG Operating Group II, L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Operating Group I, L.P., which is the sole member of The Rise Fund GenPar Advisors, LLC, which is the general partner of The Rise Fund GenPar, L.P., which is the managing member of The Rise Fund SPV GP, LLC, which is the general partner of each of The Rise Fund Sling, L.P., which directly holds 5,476,598 shares of Common Stock ("Common Stock") of Sionna Therapeutics, Inc. (the "Issuer"), and The Rise Fund Sling II, L.P. (together with The Rise Fund Sling, L.P., the "TPG Funds"), which directly holds 1,208,364 shares of Common Stock.
Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, as amended, the shares of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock, in each case of the Issuer (collectively, the "Preferred Stock"), automatically converted into shares of Common Stock upon consummation of the Issuer's initial public offering on February 10, 2025 at a conversion rate (adjusted for a reverse stock split) equal to one share of Common Stock per 1.4611 share of Preferred Stock. The shares of Preferred Stock had previously been convertible, at the option of the holder, at any time into shares of Common Stock.
On February 10, 2025, in connection with the Issuer's initial public offering, The Rise Fund Sling, L.P. acquired an aggregate of 1,125,000 shares of Common Stock at a price of $18.00 per share.
Because of the relationship between the Reporting Persons and the TPG Funds, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of the TPG Funds. Each of the TPG Funds and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such TPG Fund's or such Reporting Person's pecuniary interest therein, if any.
Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests.